8-K filed Jul 13, 2026 at 07:09 ET
Q32 Bio reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata, showing a 35.3% mean reduction in SALT score and 40% SALT-20 response in the mITT population with a favorable safety profile. The company also disclosed it paid off the remaining ~$6.8M loan from Silicon Valley Bank, eliminating debt. The data supports advancement to a registration-directed program in H1 2027, a significant milestone for this clinical-stage biotech.